By harnessing the innovative potential for circular RNAs as robust biomarkers for brain disorders, Circular Genomics is reshaping the patient-provider relationship in healthcare, elevating the precision of treatment strategies.
Our assay analyzes blood-based circular RNA biomarkers to predict a patient's response to SSRI antidepressants prior to treatment initiation. This expedites treatment and likelihood of recovery, empowering patients to make well-informed decisions about their health.
Renowned for their stability and neural tissue enrichment, circular RNAs are easily detectable in the blood, making them ideal biomarkers for enhancing brain disorder diagnosis and monitoring.
Circular RNAs offer a unique window into a patient's biological status. These biomarkers cross the blood-brain barrier, originating from the brain where they are highly enriched, and can be accessible through a simple blood test.